Application of fucoidan polysaccharide sulfate in preparing drug for preventing and/or treating diabetic cardiomyopathy

Abstract

The invention discloses a drug novel use of fucoidan polysaccharide sulfate. The use is the application of the fucoidan polysaccharide sulfate in preparing the following products: (1), a product for preventing and / or treating diabetic cardiomyopathy; (2), a product for inhibiting diabetic myocardial oxidative stress; and (3), a product for inhibiting expression and activation of PKC (Protein Kinase C) beta in diabetic cardiomyopathy; and (4), a product for relieving cardiac interstitial fibrosis of a diabetic. The fucoidan polysaccharide sulfate is preferably LMWF (Fucoidan Polysaccharide Sulfate) with weight-average molecular weight of 3-30KD. According to the pharmacodynamic experiment, the LMWF can be used for generating beneficial interference to the development of pathogenetic condition of the diabetic cardiomyopathy by strengthening the myocardial systolic function and relieving cardiac fibrosis. More importantly, the LMWF can be used for effectively inhibiting oxidative stress by regulating the activity of antioxidase, and can be used for inhibiting the expression of protein kinase C beta (PKCbeta) subtype. The LMWF is from the natural existing kelp, so that the availability and safety of the kelp are beneficial to using the fucoidan polysaccharide sulfate as a potential clinical treatment drug and preventing the diabetic cardiomyopathy.

Description

technical field [0001] The invention relates to the application of fucoidan sulfate in the preparation of drugs for preventing and / or treating diabetic cardiomyopathy. Background technique [0002] Cardiac dysfunction due to diabetic cardiomyopathy is not associated with the development of coronary atherosclerosis or hypertension. Premature diastolic dysfunction and late systolic dysfunction detected by echocardiography are two prominent mechanical injuries of the heart. Cardiac dysfunction is mainly manifested as a decrease in systolic and diastolic velocity and a decrease in myocardial contractility and compliance. Although there are many pathogenesis of diabetic cardiomyopathy, many studies related to the mechanism suggest that it is related to changes in cardiac energy metabolism [An, D. and B. Rodrigues, Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol, 2006.291(4): p.H1489-506.], impaired calcium balance...

AI Technical Summary

Problems solved by technology

Recent studies have found that LMWF can protect the kidney from ischemic refocus injury [Chen, J., et al., Low Molecular Weight Fucoidan against Renal Ischemia-Reperfusion Injury via Inhibition of the MAPK Signaling Pathway. PLoS One, 2013.8(2): p.e56224.], and whether LMWF has a protective effect on diabetic cardiomyopathy has not been studied

Images